Abstract
The work reported in this article has evaluated the relative molecular activity of the 5′-triphosphate of a novel β-l-nucleoside with an unsaturated ribose residue, β-l-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine (β-l-Fd4CTP), with that of β-l-2′,3′-dideoxy-5-fluorocytidine (β-l-FddCTP) and 2′,3′-dideoxycytidine (ddCTP), on DNA strand elongation by human immunodeficiency virus-1 reverse transcriptase (HIV RT) and human DNA polymerases α (pol α), β (pol β), γ (pol γ), and ε (pol ε). The concentrations of β-l-Fd4CTP that inhibited the yield of products by 50% were 0.20 μm, 1.8 μm, and 4.0 μm for HIV RT, pol γ, and pol β, respectively. The β-l-Fd4CTP at a concentration as high as 40 μm had no inhibitory effect on pol ε, but could inhibit pol α by 10–20% at 20 μm. TheKm and relativeVmax values of β-l-Fd4CTP, β-l-FddCTP, and ddCTP for incorporation into the standing start point of 5′-[32P]-oligonucleotide primer annealed with M13mp19 phage DNA by HIV RT and human DNA polymerases were evaluated. The efficiency of incorporation (Vmax/Km) of β-l-Fd4CTP by HIV RT was about 4-fold and 12-fold higher than that of ddCTP and β-l-FddCTP, respectively. In contrast, theVmax/Kmratio of β-l-Fd4CTP for pol γ was 7-fold lower than that of ddCTP, but 4-fold higher than that of β-l-FddCTP. Pol α could use β-l-Fd4CTP as a substrate, but only at a high concentration (>20 μm). Incorporation of β-l-Fd4CTP by pol ε could not be detected. A hypothesis about the preferable recognition of the 2′,3′-dideoxy-2′,3′-didehydro- structure of β-l-Fd4CTP to that of the 2′,3′-dideoxy-structure of β-l-FddCTP by HIV RT is discussed.
Footnotes
-
Send reprint requests to: Dr. Yung-Chi Cheng, Pharmacology Department, Yale University School of Med., 333 Cedar Street., New Haven, CT 06510.
-
This work was supported by National Institutes of Health Grant AI38204.
- Abbreviations:
- HIV
- human immunodeficiency virus type 1
- HBV
- human hepatitis B virus
- pol
- polymerase
- RT
- reverse transcriptase
- dNTP
- 2′-deoxynucleoside 5′-triphosphate
- dCTP
- 2′-deoxycytidine 5′-triphosphate
- ddNTP
- 2′,3′-dideoxynucleoside 5′-triposhate
- ddC
- 2′,3′-dideoxycytidine
- ddCTP
- 5′-triphosphate of ddC
- FddC
- 5′-fluoro-analog of ddC
- FddCTP
- 5′-triposphate of FddC
- Fd4C
- 2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine
- Fd4CTP
- 5′-triphosphate of FddC
- 3TC
- β-l-2′,3′-dideoxy-3′-thiocytidine
- Received December 2, 1997.
- Accepted January 26, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|